Bank of New York Mellon
MBX

Bank of New York Mellon’s MBX Biosciences MBX Stock Holding History

Bank of New York Mellon’s Portfolio MBX Stock Details MBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.91M Buy
88,927
+8,705
+11% +$304K ﹤0.01% 2450
2026
Q1 		$2.39M Buy
80,222
+4,960
+7% +$169K ﹤0.01% 2721
2025
Q4 		$2.37M Buy
75,262
+27,527
+58% +$668K ﹤0.01% 2738
2025
Q3 		$835K Buy
47,735
+9,703
+26% +$130K ﹤0.01% 3312
2025
Q2 		$434K Buy
38,032
+14,122
+59% +$144K ﹤0.01% 3587
2025
Q1 		$176K Sell
23,910
-4
-0% -$42 ﹤0.01% 3915
2024
Q4 		$441K Buy
+23,914
New +$510K ﹤0.01% 3588

Other funds holding MBX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $328M AUM 166.51% 1-Year Est. Return
AWA
Aaron Wealth Advisors Chicago, Illinois $1.97B AUM 36.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
Swiss National Bank
Swiss National Bank Zurich, Switzerland $191B AUM 45.21% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Bank of New York Mellon's MBX Position: Q2 2026 in Review

Bank of New York Mellon increased its MBX Biosciences (MBX) stake by 11% in Q2 2026, buying an estimated $304K and bringing the position to 88,927 shares worth $4.91M. The position accounts for ﹤0.01% of the portfolio, ranked #2450.

Bank of New York Mellon first reported a position in MBX in Q4 2024 and has held it in 7 quarters since. 56 funds tracked by Wall St. Rank hold MBX as of Q2 2026.

  • Bank of New York Mellon held 88,927 shares of MBX Biosciences worth $4.91M as of Q2 2026.
  • Bank of New York Mellon bought 8,705 MBX Biosciences shares in Q2 2026, an estimated $304K.
  • MBX Biosciences made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #2450 holding.
  • Bank of New York Mellon first reported a position in MBX Biosciences in Q4 2024 and has held it in 7 quarters since.
  • 56 funds tracked by Wall St. Rank held MBX Biosciences as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.